0.00
-0.0001(-50.00%)
Currency In USD
Address
2537 Research Boulevard
Fort Collins, CO 80526
United States of America
Phone
888 613 8802
Sector
Healthcare
Industry
Biotechnology
Employees
46
First IPO Date
July 28, 2021
| Name | Title | Pay | Year Born |
| Dr. Robert W. Buckheit Jr., Ph.D. | Chief Technology Officer | 0 | 1961 |
| Mr. Christopher Zosh | Executive Vice President of Finance, Interim Principal Financial Officer & Interim Principal Accounting Officer | 0 | 1976 |
| Dr. Blake Hawley D.V.M., M.B.A. | Executive Chairman | 0 | 1965 |
Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as expanding into fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. The company is based in Fort Collins, Colorado.